6/08/2007
Patenting Pandora’s Bug
quote:
ETC Group Will Challenge Patents on "Synthia" - Original Syn Organism Created in Laboratory
...the J. Craig Venter Institute is applying for a patent on a new biological bombshell - the world's first-ever human-made species. The novel bacterium is made entirely with synthetic DNA in the laboratory.
"Synthia may not be as cuddly as a cloned lamb, but we believe this is a much bigger deal," explains Jim Thomas of ETC Group, a civil society organization that is calling on the world's patent offices to reject the applications. "These monopoly claims signal the start of a high-stakes commercial race to synthesize and privatize synthetic life forms. Will Venter's company become the 'Microbesoft' of synthetic biology?" asks Jim Thomas.
Published on May 31, 2007, the Venter Institute's US Patent application (number 20070122826) claims exclusive ownership of a set of essential genes and a synthetic "free-living organism that can grow and replicate" that is made using those genes.
"Synthetic biologists have already assembled the poliovirus from off-the-shelf DNA, a feat that its constructor called 'a giant wake up call' because of the biowarfare implications. Syns are being hyped as a green, climate-change solution in order to deflect concerns that they could be used as bioweapons," adds Silvia Ribeiro of ETC Group.
The patent application is also a wake-up call to synthetic biologists who are advocating for "open source" biology - the idea that the fundamental tools and components of synthetic biology should be freely accessible to researchers. In the June 4 issue of Newsweek Craig Venter boasts, "If we made an organism that produced fuel, that could be the first billion- or trillion-dollar organism. We would definitely patent that whole process." In 2005, Venter founded Synthetic Genomics, Inc. to commercialize synthetic microbes for use in energy, agriculture and climate change remediation.
ETC Group - Publications - Patenting Pandora’s Bug: Goodbye, Dolly...Hello, Synthia! J. Craig Venter Institute Seeks Monopoly Patents on the World’s First-Ever Human-Made Life Form
Patent application
ETC Group Will Challenge Patents on "Synthia" - Original Syn Organism Created in Laboratory
...the J. Craig Venter Institute is applying for a patent on a new biological bombshell - the world's first-ever human-made species. The novel bacterium is made entirely with synthetic DNA in the laboratory.
"Synthia may not be as cuddly as a cloned lamb, but we believe this is a much bigger deal," explains Jim Thomas of ETC Group, a civil society organization that is calling on the world's patent offices to reject the applications. "These monopoly claims signal the start of a high-stakes commercial race to synthesize and privatize synthetic life forms. Will Venter's company become the 'Microbesoft' of synthetic biology?" asks Jim Thomas.
Published on May 31, 2007, the Venter Institute's US Patent application (number 20070122826) claims exclusive ownership of a set of essential genes and a synthetic "free-living organism that can grow and replicate" that is made using those genes.
"Synthetic biologists have already assembled the poliovirus from off-the-shelf DNA, a feat that its constructor called 'a giant wake up call' because of the biowarfare implications. Syns are being hyped as a green, climate-change solution in order to deflect concerns that they could be used as bioweapons," adds Silvia Ribeiro of ETC Group.
The patent application is also a wake-up call to synthetic biologists who are advocating for "open source" biology - the idea that the fundamental tools and components of synthetic biology should be freely accessible to researchers. In the June 4 issue of Newsweek Craig Venter boasts, "If we made an organism that produced fuel, that could be the first billion- or trillion-dollar organism. We would definitely patent that whole process." In 2005, Venter founded Synthetic Genomics, Inc. to commercialize synthetic microbes for use in energy, agriculture and climate change remediation.
ETC Group - Publications - Patenting Pandora’s Bug: Goodbye, Dolly...Hello, Synthia! J. Craig Venter Institute Seeks Monopoly Patents on the World’s First-Ever Human-Made Life Form
Patent application
6/05/2007
Genetic Variations May Predispose Some Men to Suicidal Thoughts During Short-Term Treatment for Depression
Quote:
Genetic variations may help explain why some men with depression develop suicidal thoughts and behaviors after they begin taking antidepressant medications, while most do not, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Although most patients with depression respond favorably to antidepressant medications, a very small subgroup may experience worse symptoms after beginning treatment, according to background information in the article.
Studies that link genes to illnesses are most compelling when there is additional evidence of that gene’s function, the authors note. “We recently observed an association between the same CREB1 polymorphisms and a measure of anger expression among males but not females in a sample of 94 patients with major depressive disorder; hostility and anger expression have also been associated with suicide,” they write.
“If replicated, this finding would suggest that pharmacogenetic testing could facilitate the identification of the small subset of individuals at greater risk during short-term antidepressant treatment,” the authors conclude.
(Arch Gen Psychiatry. 2007;64:689-697. Available pre-embargo to the media at www.jamamedia.org.)
Newswise Medical News | Genetic Variations May Predispose Some Men to Suicidal Thoughts During Short-Term Treatment for Depression
Genetic variations may help explain why some men with depression develop suicidal thoughts and behaviors after they begin taking antidepressant medications, while most do not, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Although most patients with depression respond favorably to antidepressant medications, a very small subgroup may experience worse symptoms after beginning treatment, according to background information in the article.
Studies that link genes to illnesses are most compelling when there is additional evidence of that gene’s function, the authors note. “We recently observed an association between the same CREB1 polymorphisms and a measure of anger expression among males but not females in a sample of 94 patients with major depressive disorder; hostility and anger expression have also been associated with suicide,” they write.
“If replicated, this finding would suggest that pharmacogenetic testing could facilitate the identification of the small subset of individuals at greater risk during short-term antidepressant treatment,” the authors conclude.
(Arch Gen Psychiatry. 2007;64:689-697. Available pre-embargo to the media at www.jamamedia.org.)
Newswise Medical News | Genetic Variations May Predispose Some Men to Suicidal Thoughts During Short-Term Treatment for Depression
